Safety and Efficacy of the Bi-Aspheric Monofocal IOL

Who May Qualify: 1. Subjects 18 years of age or older who have been implanted with aspicio™ monofocal intraocular lens in at least 1 eye 2. Willingness to cooperate with and complete all post-operative visits 3. Ability to comprehend and sign an willing to sign a consent form Who Should NOT Join This Trial: 1. Any pathology that could reduce Visual Acuity (VA) (including amblyopia, severe corneal dystrophy, diabetic retinopathy, extremely narrow anterior chamber depth, microphthalmos, clinically significant macular/RPE changes, retinal detachment, corneal transplant, chronic sever uveitis, choroidal hemorrhage, recurrent severe inflammation of the anterior or posterior segment of unknown etiology, iris neovascularization, medically controlled or uncontrolled glaucoma, clinically significant macular degeneration, or diagnosis of pseudoexfoliation). 2. Previous ocular surgery (including YAG-laser) or trauma 3. Clinically significant irregular astigmatism 4. Concomitant severe eye disease 5. Pregnant or lactating 6. Any other ocular or systemic condition which, in the opinion of the investigator, should exclude the subject from the study 7. Concurrent participation in another drug or device investigation 8. May be expected to require other ocular surgery during the study Always talk to your doctor about whether this trial is right for you.